Successful treatment of Wegener’s granulomatosis associated scleritis with rituximab

Comment Rituximab is a humanised monoclonal antibody against the CD20 antigen that is expressed on the cell surface during early pre-B cell development and persists through all stages of B cell differentiation. 4 It results in rapid depletion of CD20 positive B lymphocytes from the circulating blood and is well tolerated. [...]in this case the prompt improvement was attributed to rituximab, rather than cyclophosphamide.